Biochemical markers of bone turnover

Mark DB, Felker GM. 2004 B-type natriuretic peptide-a biomarker for all seasons? N Engl J Med 350:718–720. Mundy GR, Chen D, Oyajobi BO, 2003. Bone remodeling. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol 1, 5th ed. American Society for Bone and Mineral Research, Washington, DC, pp. 46–58. Taber CW, Bone 1993 In: Thomas CL (ed) Taber's Cyclopedic Medical Dictionary. Vol. 1, 17th ed. F.A. Davis Company, Philadelphia, USA, pp. 252–254. Taber CW, 1993, Skeleton. In: Thomas CL (ed) Taber's Cyclopedic Medical Dictionary. Vol 1, 17th ed. F.A. Davis Company, Philadelphia, USA pp. 1806–1808. Gray H. 1991 Osteology. In: Gray's Anatomy. The Classic First Edition. The Promotional Reprint Company, London, England, pp. 1–5. Halleen JM. 2003 Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23:1027–1029 Sassi ML, Eriksen H, Risteli L et al. 2000 Immunochemical characterization of assay for carboxyterninal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–373. Garnero P, Jouvenne P, Buchs N, Delmas PD, Miossec P. 1999. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone 24:381–385. Whitson H, DeMarco D, Reilly D, et al. 2002 Uncoupling of bone turnover following hip replacement. Calcif Tissue Int 71:14–19. Khan AA, Bilezikian JP, Kung AW, et al. 2004 Alendronate in primary hyperparathyroidism: a doubleblind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:3319–3325. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP, 1992. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 74:481–486. Khosla S, Kleerekoper M, 2003 Biochemical markers of bone turnover. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolis, 5th ed. American Society for Bone and Mineral Research, Washington, DC pp. 166–172. Magnusson P, Larsson L, Magnusson M, Davie MW, Sharp CA. 1999 Isoforms of bone alkaline phosphatase: characterization and origin in human trabecular and cortical bone. J Bone Miner Res 14:1926–1933. Chen P, Satterwhite JH, Licata AA, et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970. Schlemmer A, Hassager C, Jensen SB, Christiansen C, 1992. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476–480. Rogers A, Hannon RA, Eastell R 2000 Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398–1404. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536. Eastell R. 1999 Biochemical markers of bone turnover in Paget's disease of bone. Bone 24:49S-50S. Seibel MJ, Lang M, Geilenkeuser WJ, 2001 Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47:1443–1450. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348–360. Franke S, Lehmann G, Abendroth K, Hein G, Stein G 1998 PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res 3:81–88. Montagnani A, Gonnelli S, Cepollaro C et al 2003. A new serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy. Eur J Intern Med 14:172–177. Rosen HN, Moses AC, Garber J, et al. 2000 Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coeffient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103. Rosen CJ, Hochberg MC, Bonnick SL, et al. 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151 Miller PD, McClung MR, Macovei L, et al. 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315–1322. Greenspan SL, Resnick NM, Parker RA, 2005 Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767. Valimaki MJ, Tahtela R. 2005 Serum tartrate-resistant acid phosphatase 5b or amino-terminal propeptide of type I procollagen for monitoring bisphosphonate theraopy in postmenopausal osteoporosis? Clin Chem 51:2382–2385. Tahtela R, Seppanen J, Laitinen K, Katajamaki A, Risteli J, Valimaki MJ. 2005 Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen aminoterminal propeptide. Osteoporos Int 16:1109–1116. Gundberg CM, Looker AC, Nieman SD, Calvo MS. 2002 Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone 31: 703–708. Greenspan SL, Emkey RD, Bone HG, et al. 2002 Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875–883. Meunier PJ, Roux C, Seeman E, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468. Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas PD. 2003 Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 33:159–166. Ravn P, Thompson DE, Ross PD, Christiansen C. 2003 Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33:150–158. Koizumi M, Yamada Y, Takiguchi T, et al. 1995 Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 121:542–548. Luftner D, Richter A, Geppert R, Wernecke KD, Possinger K. 2003 Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 23:1017–1026. Garnero P, Geusens P, Landewe R. 2003 Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 21:S54-S58. Eagleton A, Hoyle N, Blumsohn A, Eastell R. 2002 Diurnal rhythm of serum-based markers of bone turnover: impact on monitoring response to risedronate in osteoporosis. J Bone Miner Res Suppl: American Society of Bone and Mineral Metabolism. Available from: http:www.asbmr.org. Accessed December 16th 2005. van Coeverden SC, Netelenbos JC, de Ridder CM, Roos JC, Popp-Snijders C, Delemarre-van de Waal HA. 2002 Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) 57:107–116. Rabinovich CE. 2002 Bone metabolism in childhood rheumatic disease. Rheum Dis Clin North Am 28:655–667, vii–viii. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. 1999 Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14:1614–1621. Szulc P, Claustrat B, Marchand F, Delmas PD. 2003 Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 88:5240–5247. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. 2002. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31: 57–61. Schlemmer A, Hassager C 1999 Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140:332–337. Suliman AM, Freaney R, Smith TP, McBrinn Y, Murray B, McKenna TJ. 2003 The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 59:380–387. Caillot-Augusseau A, Vico L, Heer M, et al. 2000 Space flight is associated with rapid decreases of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation: observations in two cosmonauts. Clin Chem 46:1136–1143. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. 2002 Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890. Watanabe Y, Ohshima H, Mizuno K, et al. 2004 Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 19:1771–1778. Licata A. 2003 Osteoporosis in men: suspect secondary disease first. Cleve Clin J Med 70:247–254. Guillemant JA, Accarie CM, de la Gueronniere V, Guillemant SE. 2003 Different acute responses of serum type I collagen telopeptides, CTX, NTX and ICTP, after repeated ingestion of calcium. Clin Chim Acta 337: 35–41. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468. Pols HA, Felsenberg D, Hanley DA, et al. 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax international trial study group. Osteoporos Int 9:461–468. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056. Passeri G, Pini G, Troiano L, et al. 2003 Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab 88:5109–5115. Vieth R. 2005 The role of vitamin D in the prevention of osteoporosis. Ann Med 37:278–285. Canalis E, Giustina A. 2001 Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86:5681–5685. Kanis JA, Johansson H, Oden A, et al. 2004 A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. 2005. Use of oral corticosteroids and risk of fractures. June 2000. J Bone Miner Res 20:1487–1494; discussion 1486. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. 2000 Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005;20:464–470. Looker AC, Bauer DC, Chesnut CH, 3rd, et al. 2000 Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11: 467–480. Cummings SR, Nevitt MC, Browner WS, et al. 1995 Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 332: 767–773. Garnero P, Hausherr E, Chapuy MC, et al. 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 11: 1531–1538. Garnero P, Dargent-Molina P, Hans D, et al. 1998 Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563–569. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. 2002 Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 13:523–526. Bruyere O, Collette J, Delmas P, et al. 2003 Interest of biochemical markers of bone turnover for long-term prediction of new vertebrate fracture in postmenopausal osteoporotic women. Maturitas 44:259–265. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. 1997 Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab 82:719–724. Kleerekoper M. 2001 Biochemical markers of bone turnover: why theory, research, and clinical practice are still in conflict. Clin Chem 47:1347–1349. Recker R, Stakkestad JA, Chesnut CH, 3rd, et al. 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899. Clowes JA, Peel NF, Eastell R. 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123. Bauer DC, Garnero P, Hochberg MC, et al. 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299. Seibel MJ, Naganathan V, Barton I, Grauer A. 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19:323–329. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922–930. Black DM, Cummings SR, Karpf DB, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541. Black DM, Thompson DE, Bauer DC, et al. 2000 Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group. J Clin Endocrinol Metab 85:4118–4124. Bone HG, Greenspan SL, McKeever C, et al. 2000 Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group. J Clin Endocrinol Metab 85:720–726. Karpf DB, Shapiro DR, Seeman E, et al. 1997 Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate osteoporosis treatment study groups. JAMA 277:1159–1164. Liberman UA, Weiss SR, Broll J, et al. 1995 Effect of oral aldendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437–1443. Lindsay R, Nieves J, Formica C, et al. 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555. Reid IR, Brown JP, Burckhardt P, et al. 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661. Heaney RP, Zizic TM, Fogelman I, et al. 2002 Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13:501–505. Chesnut III CH, Skag A, Christiansen C, et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249. Chesnut CH 3rd, Silverman S, Andriano K, et al. 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 109:267–276. Orwoll E, Ettinger M, Weiss S, et al. 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610. Reginster J, Minne HW, Sorensen OH, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91. Delmas PD, Recker RR, Chesnut CH, 3rd, et al. 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: resutls from the BONE study. Osteoporos Int 15:792–798. Tanko LB, Felsenberg D, Czerwinski E, et al. 2003 Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254:159–167. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. 2002 Effect of lower doses of conjugated equine estrogen with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668–2676. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12: 922–930. Tonino RP, Meunier PJ, Emkey R, et al. 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. J Clin Endocrinol Metab 85: 3109–3115. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, et al. 2000 Serum CrossLaps for monitoring the responsein individuals undergoing antiresorptive therapy. Bone 26: 505–511. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618–1623. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. 2000 Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11: 434–442. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076. Body JJ, Gaich GA, Scheele WH, et al. 2002. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535. Black DM, Greenspan SL, Ensrud KE, et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215. Rittmaster RS, Bolognese M, Ettinger MP, et al. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134. Dobnig H, Sipos A, Jiang Y, et al. 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977. Black DM, Bilezikian JP, Ensrud KE, et al. 2005 One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565. Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA. 2006 Effect of teriparatide [rhPTH(1–34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21:283–291. Deal C, Omizo M, Schwartz EN, et al. 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905–1911. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R. 1998 Alendronate does not block the anabolic effect, of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13:1051–1055. Reginster JY, Seeman E, De Vernejoul MC, et al 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822. Marie PJ, Ammann P, Boivin G, Rey C. 2001 Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121–129. Lyles KW, Siris ES, Singer FR, Meunier PJ. 2001 A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 16:1379–1387. Reid IR, Miller P, Lyles K, et al. 2005 Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898–908. Roodman GD, Windle JJ. 2005 Paget disease of bone. J Clin Invest 115:200–208. Bekker PJ, Holloway DL, Rasmussen AS, et al. 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066. Brown JP, Kendler DL, McClung MR, et al. 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103–111. Schnitzer T, Bone HG, Crepaldi G, et al. 2000 Therapeutic equivalence of alendonate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group. Aging (Milano) 12:1–12. Garnero P, Landewe P, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847–2856. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. 2005 Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 64:1137–1140. Dolan AL, Moniz C, Abraha H, Pitt P. 2002 Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology (Oxford) 41:1047–1051.